Consistently demonstrating the results you need for the outcomes that matter

SAPIEN valve technology: the valve design that has revolutionized how we treat severe symptomatic aortic stenosis today, leveraging decades of Edwards surgical valve innovation and expertise.

Only SAPIEN 3 transcatheter aortic heart valve replacement (TAVR) is proven superior* to surgery in low-risk patients1

Proven in the PARTNER 3 Low-Risk Trial

  • 8.5% death, stroke, rehospitalization versus 15.1% for surgery at 1 year*1

*In the PARTNER 3 trial, SAPIEN 3 TAVR was proven superior to surgery on the primary endpoint of all-cause death, all stroke, and rehospitalization (valve-related or procedure-related, and including due to heart failure) at one year and multiple pre-specified secondary endpoints in low-risk patients.

PVL and pacemaker rates similar to surgery at 1 year1


moderate or
severe PVL


new permanent

Consistently strong outcomes for a variety of patient morphologies:

  • Excellent clinical outcomes in low-risk bicuspid patients2
  • Consistently strong outcomes across indicated annular sizes3

Join Edwards Connect

Our exclusive portal grants you access to our latest educational tools, resources, and more to help you communicate with your patients and referrers.

Connect with us

The Edwards SAPIEN platform brochure

When it comes to lifetime management, learn more about how the Edwards SAPIEN 3 platform is designed to deliver a TAVR experience an implanter can count on, starting with the index procedure.

View the brochure

Designed to deliver a TAVR experience an implanter can count on

Edwards Commander delivery system

Predictability and control to meet the increasing complexity of your procedures.

Edwards eSheath+ introducer set

Low profile and expandable sheath design

Edwards eSheath+ Introducer set

*16F & 6.0mm for 29mm SAPIEN 3 Ultra RESILIA Valve

References:   1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705. 2. Williams MR, Jilaihawi H, Makkar R, et al. The PARTNER 3 bicuspid registry for transcatheter aortic valve replacement in low-surgical-risk patients. J Am Coll Cardiol Intv. 2022;15(5):523-32. 3. Eng MH, Abbas AE, Hahn RT, et al. Real world outcomes using 20 mm balloon expandable SAPIEN 3/ultra valves compared to larger valves (23, 26, and 29 mm)- a propensity matched analysis. Catheter Cardiovasc Interv. 2021;98(6):1185-92.